ArticleEJNMMI physics2020
Human dosimetry of free
Article in EJNMMI physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Spatiotemporal Imaging Dynamics and Divergent Immune Mechanisms ofChemical & biomedical imaging · 2026Article
- Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- A study of differences in absorbed dose estimates by images used in dosimetry of Lu-177-DOTATATE therapy.Radiological physics and technology · 2025Article
- Novel astatine (European journal of nuclear medicine and molecular imaging · 2025Article
- Biodistribution and dosimetry of the PET radioligand [EJNMMI research · 2024Article
- In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211.EJNMMI radiopharmacy and chemistry · 2024Article
- Article
- Radiochemistry for positron emission tomography.Nature communications · 2023Review
- Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Oxidation ofInternational journal of molecular sciences · 2022Article
- Manual on the proper use of meta-[Annals of nuclear medicine · 2022Article
- Review
- Nonclinical study and applicability of the absorbed dose conversion method with a single biodistribution measurement for targeted alpha-nuclide therapy.EJNMMI physics · 2021Article
- Enhancing the Therapeutic Effect of 2-Cancers · 2021Article
- Production, purification and availability ofNuclear medicine and biologyReview
- Synthesis and preliminary evaluation ofNuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsMale C57BL/6 N mice were administered 0.13 MBq of free
resultsHigh uptake of free
conclusionsThe absorbed doses of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.